Introduction {#S1}
============

In recent decades, multiple drug-resistant and carbapenem-resistant Enterobacteriaceae have increased in abundance, particularly *Klebsiella pneumoniae* (*KP*), *Escherichia coli*, *Enterobacterial* spp., *Proteus* spp., and *Serratia mucosa*, greatly limiting the efficacy of antibiotic treatment. Tigecycline is currently widely used in clinical practice as an anti-infective treatment and has become the most important antibiotic for treating carbapenem-resistant *Acinetobacter baumannii* and carbapenem-resistant *Enterobacteriaceae.* However, *A. baumannii*, *E. coli*, and *K. pneumoniae* have shown resistance to tigecycline. Additionally, various mechanisms have been reported to confer tigecycline resistance, with most studies focusing on resistance-nodulation cell division transporters, mainly among AcrAB-TolC efflux pumps, while other pumps and various control pathways are also reported to be associated with tigecycline resistance ([@B22]; [@B6]; [@B25]; [@B11]).

[@B23] determined the tigecycline resistance mechanism in 26 strains of tigecycline-non-susceptible KP and found that the resistance of nine strains could not be explained by existing mechanisms. Recent studies revealed a co-regulatory effect between antibiotic resistance and metal resistance. [@B24] reported that the CzcR-CzcS two-component system (TCS) in *Pseudomonas aeruginosa* participates in metal detoxification and antibiotic resistance, mainly by co-regulating cross-resistance between Zn (II) and carbapenems antibiotics. [@B21] reported that in *P. aeruginosa*, the CzcR-CzcS TCS induced resistance to cadmium, zinc, and cobalt through over-expression of the efflux pump system, resulting in an increase in the MICs of carbapenems. In a study of metal resistance and its relationship with antibiotic resistance, [@B20] found that metal resistance and antibiotic resistance genes were located at the same site in the cell, and a single resistance mechanism (such as the efflux pump) could result in resistance to either antibiotics or metal. [@B13] studied the relationship between heavy metals and bacterial antibiotic resistance in pig manure, and revealed that the presence of copper and zinc was significantly correlated with the increased drug resistance rate of β-lactam antibiotics, while the presence of mercury was significantly correlated with the low drug resistance of *E. coli* to β-lactams, aminoglycosides, and other antibiotics. These studies suggest that bacterial resistance to metals is associated with antibiotic resistance.

The CusS-CusR TCS is associated with bacteria resistant to the heavy metals copper/silver, in which copper/silver ions stimulate the phosphorylation of the outer membrane protein, CusS; the phosphorylated CusS phosphorylates the translation regulator, CusR. The phosphorylated CusR promotes higher expression of the genes encoding the efflux pump CusCFBA, which pumps the copper/silver out of the bacteria, thus leading to bacteria that are resistant to heavy metals. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of CusS-CusR TCS is shown in [Figure 1](#F1){ref-type="fig"}.

![KEGG pathway of the CusS-CusR TCS.](fmicb-10-03159-g001){#F1}

However, only a few studies have focused on the tolerance of *K. pneumoniae* to heavy metals and its association with antibiotic resistance. Accordingly, in this study, we induced three forms of carbapenem-resistant *Klebsiella pneumoniae* (CRKP) resistance to tigecycline *in vitro* and identified the differentially expressed genes using transcriptome sequencing. In particular, we focused on the CusS-CusR TCS to determine its potential role in tigecycline resistance in nine CRKP strains that evolved from the three parental strains *KPN222 (A)*, *KPN114 (B)*, and *KPN315 (C)*.

Materials and Methods {#S2}
=====================

Antimicrobial Susceptibility Testing {#S2.SS1}
------------------------------------

Antibiotic susceptibility testing was performed using the Vitek 2 system (BioMérieux, Marcy-l Étoile, France). The MICs of tigecycline and polymyxin B were determined using the micro-broth dilution method (BIO-KONT Co., Ltd., Wenzhou, China). The breakpoints of tigecycline and polymyxin B were interpreted according to the Clinical and Laboratory Standards Institute guidelines ([@B15]). *E. coli* ATCC25922 and *P. aeruginosa* ATCC27853 were used as quality controls.

Laboratory Evolution of Tigecycline-Resistant Mutants {#S2.SS2}
-----------------------------------------------------

Independent single colonies of the CRKP strains *KPN222 (A)*, *KPN114 (B)*, and *KPN315 (C)* were grown overnight at 37°C. The cultures were then inoculated into Luria--Bertani (LB) agar with serially increasing concentrations of tigecycline, starting at a value equal to half of the MIC of the original strain and doubled when bacteria grew on the plates; the final concentration of tigecycline was 256 μg/mL. The resistant strains were transferred to a blood agar plate and continuously transferred 10 times, and then the MIC of tigecycline was determined to obtain the stable resistant strain. The tigecycline resistant strains were stored at −80°C until analysis.

RNA Extraction, Sequencing, and Data Analysis {#S2.SS3}
---------------------------------------------

The isolates were grown in high-osmolality LB broth at 37°C until the early exponential phase, and then RNA was extracted using the RNApure Bacteria kit (CWBio Co., Beijing, China) according to the manufacturer's protocol. The concentration of RNA was measured using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, United States). RNA sequencing was performed using a HiSeq 2000 sequencer (Illumina, San Diego, CA, United States) and *de novo* assembly was carried out using Trinity software^[1](#footnote1){ref-type="fn"}^. BLASTn ([@B1]) was used to analyze Unigene NT with a Blastx ([@B1]) or Diamond ([@B3]) search on Unigene for NR; KOG, KEGG, and SwissProt were used to analyze Blast2GO ([@B7]) and the NR annotation results for Gene Ontology (GO) annotation. Bowtie 2 ([@B16]) was used to compare the clean reads with the corresponding sequences in Unigene, and RSEM ([@B17]) was then used to calculate the gene expression levels of each sample. The PossionDis method was used for differential gene detection.

Quantitative PCR and Standard PCR {#S2.SS4}
---------------------------------

The expression levels of the CusS-CusR TCS were determined using quantitative qPCR. The primers used for the CusS-CusR TCS and other genes associated with tigecycline resistance are shown in [Table 1](#T1){ref-type="table"}. The primers used for the AcrAB-TolC efflux pump-associated genes *soxS*, *acrB*, *rarA*, *ramA*, *ramR*, *marA*, *tolC*, and *acrA* were obtained from the literature ([@B10]). The primers associated with the SdiA-AcrEF and RarA-OqxAB efflux pump are also shown in [Table 2](#T2){ref-type="table"}. Total bacterial RNA was extracted using the RNA Pure Bacteria kit (CWBIO Co., Beijing, China). cDNA was then synthesized using a Revert Aid First Strand cDNA Synthesis kit (Thermo Fisher Scientific). Finally, quantitative PCR (qPCR) was performed with the UltraSYBR Mixture kit (CWBIO Co., Beijing, China) using a Cobas z 480 analyzer (LightCycler 480, Roche, Basel, Switzerland) with initial incubation at 95°C for 10 min, followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. The melting curve fluorescence was evaluated at five times per degree Celsius from 60 to 95°C. Each reaction was carried out in triplicate. For all samples, a housekeeping gene (16S rRNA-F: 5′-GTGCCAGCMGCCGCGGTAA-3′, 16S rRNA-R: 5′-GGCGTGGACTTCCAGGGTATCT-3′) ([@B5]) was used to normalize the expression of genes. The threshold cycle (CT) numbers were confirmed using the detection system software, and the data were analyzed using the 2^ΔΔCt^ method. Gene expression levels were determined and compared with those of wild-type strains (*A1*, *B1*, and *C1*, expression = 1).

###### 

Primers of CusS-CusR TCS and other genes associated with tigecycline resistance.

  **Genes**    **Primers F/R (5′→3′)**                      **Length (nt)**   **Annealing**
  ------------ -------------------------------------------- ----------------- ---------------
  *cusE*       CGGATTGCCCGTTATTC GGGGACTGCTCCTCGTAT         230               55
  *cusS*       GCAACAAATCAGCACCAC GCTAAAGAGCACTTCACCC       148               55
  *cusR*       GGCACGATTGAACACAGGG CCGAGAGGTCAGCCACTTT      160               58
  *cusC*       TGACAAGCCGACCACACA GCTCAACGAAAGCATAGGAC      257               55
  *cusF*       TTGGTGCCTTCTCTGTCA CGTGCGAAATGGTAATCT        162               56
  *cusB*       CAGGTCCGTCTCCAGGTTT TTGGTATCAGCAGCATCTCC     103               56
  *cusA*       GTGGCGTTGTCAATCTGCT TCCGTTCTGCCCTGGTG        223               57
  *tex(T)\**   GGACCCGTTGGACTGACTA CACCCATTGGTAAGGCTAAG     193               55
  *tet(A)\**   CAGGCAGGTGGATGAGGAA GCAGGCAGAGCAAGTAGAGG     173               58
  *acrE*       ATGCCTCCGTGATGTTGG TCCGCTTCCGCTTTGA          175               56
  *acrF*       GTGCTCTCTGCGGTATTCG TGAGGCTGGCTTCAACAA       162               55
  *oqxA*       CGCAGCTTAACCTCGACTTCA ACACCGTCTTCTGCGAGACC   168               57
  *oqxB*       CGAAGAAAGACCTCCCTACC CGCCGCCAATGAGATACA      178               58

\*:

tex (T)

and

tet (A)

were detected by standard PCR and confirmed the mutant by Sanger sequencing.

###### 

Antibiotics susceptibility of primary strains and induced strains.

  **Antibiotics**                  **MIC (μg/mL) S/I/R**                                                                  
  -------------------------------- ----------------------- -------- -------- -------- -------- -------- -------- -------- --------
  Amikacin                         ≤2 S                    ≤2 S     ≤2 S     ≤2 S     ≤2 S     ≤2 S     ≤2 S     ≤2 S     ≤2 S
  Tobramycin                       ≥16 R                   ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     4 S      4 S      4 S
  Minocycline                      ≥16 R                   ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     ≥16 R
  Trimethoprim--Sulfamethoxazole   ≥320 R                  ≥320 R   ≥320 R   ≥320 R   ≥320 R   ≥320 R   ≥320 R   ≥320 R   ≥320 R
  Cefoperazone/sulbactam           ≥64 R                   ≥64R     ≥64 R    ≥64R     ≥64 R    ≥64R     ≥64 R    ≥64R     ≥64 R
  Levofloxacin                     ≥8 R                    ≥8 R     ≥8 R     ≥8 R     ≥8 R     ≥8 R     ≥8 R     ≥8 R     ≥8 R
  Ciprofloxacin                    ≥4 R                    ≥4 R     ≥4 R     ≥4 R     ≥4 R     ≥4 R     ≥4 R     ≥4 R     ≥4 R
  Cefepime                         ≥32 R                   ≥32R     ≥32 R    ≥32R     ≥32 R    ≥32R     ≥32 R    ≥32R     ≥32 R
  Aztreonam                        ≥64 R                   ≥64R     ≥64 R    ≥64R     ≥64 R    ≥64R     ≥64 R    ≥64R     ≥64 R
  Piperacillin--Tazobactam         ≥128 R                  ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R
  Ceftazidime                      ≥64 R                   ≥64R     ≥64 R    ≥64R     ≥64 R    ≥64R     32 R     32 R     32 R
  Amoxicillin/clavulanic- acid     ≥128 R                  ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R   ≥128 R
  Imipenem                         ≥16 R                   ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     ≥16 R
  Meropenem                        ≥16 R                   ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     ≥16 R    ≥16R     ≥16 R
  Polymyxin B\*                    ≤0.5 S                  ≤0.5 S   ≤0.5 S   ≤0.5 S   ≤0.5 S   ≤0.5 S   ≤0.5 S   ≤0.5 S   ≤0.5 S
  Tigecycline\*                    0.5 S                   16 R     32 R     0.5 S    16 R     32 R     0.5 S    16 S     32 R

MIC, minimal inhibitory concentration; S, sensitive; I, intermediary; R, resistance; \*: tigecycline and polymyxin B antibiotic susceptibility were determined by micro-broth dilution method.

The mutations of *tex (T)* and *tex (A)*, which are associated with tetracycline resistance, were detected using the standard PCR. The DreamTaq PCR Master Mix kit (Thermo Fisher Scientific) was used and the reaction system contained 25.0 μL of 2 × Dream Taq PCR Master Mix, 0.4 μL of forward and reverse primers (10 mol/L), and 4.0 μL of DNA template supplemented with 50.0 μL ddH~2~O. The reaction conditions were as follows: 95°C for 1 min; followed by 30 cycles of 95°C at 30 s, 50°C for 30 s, and 72°C for 1 min; with a final extension at 72°C for 8 min. All qPCR and standard PCR products were confirmed using agarose gel electrophoresis and sequencing.

Deletion and Complementation of the Gene *cusR* {#S2.SS5}
-----------------------------------------------

Based on the homologous recombination technology, the deletion strain of the △*cusR* gene was constructed using the suicide vector pKO3-Km plasmid, and the gene fragment containing the activation region and the transcriptional termination region of the coding region of the *C-*△*cusR* gene was amplified. The gene fragment was cloned into the pGEM-T-easy plasmid and transferred to the deletion strain to construct the complemented strain of the *C*-△*cusR* gene. The primers are shown in [Table 4](#T4){ref-type="table"}.

Results {#S3}
=======

Antibiotic Susceptibility of the Strains {#S3.SS1}
----------------------------------------

All strains were resistant to tobramycin, minocycline, trimethoprim--sulfamethoxazole, cefoperazone/sulbactam, levofloxacin, ciprofloxacin, cefepime, aztreonam, piperacillin--tazobactam, ceftazidime, amoxicillin/clavulanic acid, imipenem, and meropenem. The strains were only sensitive to amikacin and polymyxin B with MICs of 2 and 0.5 μg/mL, respectively. The tigecycline MIC of *A1*, *B1*, and *C1* was 0.5 μg/mL; that of *A2*, *B2*, and *C2* was 16 μg/mL; and that of *A3*, *B3*, and *C3* was 32 μg/mL. Antibiotic susceptibility of the primary strains and induced strains is shown in [Table 2](#T2){ref-type="table"}.

RNA Sequencing {#S3.SS2}
--------------

The differentially expressed genes identified by RNA-sequencing are shown in [Table 3](#T3){ref-type="table"} and [Supplementary Material](#SM1){ref-type="supplementary-material"}. Unigene 28_All was 4997 bp long and the NCBI BLAST revealed that it contained *cusE*, *cusS*, *cusR*, *cusC*, and *cusF*. Unigene274_All was 1090 bp long and contained *cusA*. Unigene1733_All was 1111 bp long and contained *cusB*. These three genes showed higher expression in *C2* and *C3* than in *C1*. Unigene1142_All was 2137 bp long, annotated to the transcriptional regulatory gene *ramA* in the genes encoding the AcrAB-TolC efflux pump, and highly expressed in *B2* and *B3*, with *B2/B1* log~2~ fold-change = 3.31 and B3/B1 log~2~ fold-change = 3.61.

###### 

Differential expression genes come from RNA sequencing.

  **Gene ID**       **log~2~Fold change**   
  ----------------- ----------------------- ------------------
  Unigene 28_All    13.8(*C*2/*C*1)         14.24(*C*3/*C*1)
  Unigene274_All    10.59(*C*2/*C*1)        10.94(*C*3/*C*1)
  Unigene1733_All   6.32(*C*2/*C*1)         6.52(*C*3/*C*1)
  Unigene1142_All   3.31(*B*2/*B*1)         3.61(*B*3/*B*1)

###### 

Primers of deletion and complement the gene of *cusR*.

  **Name**      **Primer**         **5′→3′**
  ------------- ------------------ ------------------------------------------
  *△cusR*       C3-△cusR-A         GTAT[GCGGCCGC]{.ul}CACGACGGGC TTCTTC
                C3-△cusR-B         AGGTCGTCTGGACGGTTTGCATG CTCCCCGGCTGGCTGC
                C3-△cusR-C         GCAGCCAGCCGGGGAGCATGCA AACCGTCCAGACGACCT
                C3-△cusR-D         GTAT[GCGGCCGC]{.ul}GATTCTCGGAG GTGATGTT
  *C-△cusR*     C3-△cusR-F         GAGT[CCATGG]{.ul}ATGAAAATATTA ATCGTTGA
                C3-△cusR-R         GAGT[GTCGAC]{.ul}TGGAGATCCCGG ATGCATAG
  pKO3-Km       pKO3-Km-F          AATAAGCGGATGAATGGCAG
                pKO3-Km-R          TCCCTCACTTTCTGGCTGG
  pGEM-T-easy   pGEM-T-easy-km-F   GCGAATTGGGCCCGACGTC
                pGEM-T-easy-km-R   CGCAGCCGAACGACCGAG
  *cusR*        C3-*cusR*-F        GGCACGATTGAACACAGGG
                C3-*cusR*-R        CCGAGAGGTCAGCCACTTT
  *16s rRNA*    16s rRNA-F         AAAGCGTGGGGAGCAAACAG
                16s rRNA-R         CCGCTGGCAACAAAGGATAA

"\_\_" enzyme cutting site;

Nco

I :CCATGG;

Sal

I :GTCGAC;

Not

I :GCGGCCGC.

Quantitative PCR {#S3.SS3}
----------------

The relative expression levels (fold-change) of genes related to the AcrAB-TolC efflux pump (*soxS*, *acrB*, *rarA*, *ramA*, *ramR*, *marA*, *tolC*, and *acrA*) in *A2/A1* and *A3/A1*, *B2/B1* and *B3/B1*, and *C2/C1* and *C3/C1* are shown in [Figure 2](#F2){ref-type="fig"}. The expression level of AcrAB-TolC efflux pump-related factors was the highest in group B. The relative expression levels (fold-change) of genes related to the CusS-CusR TCS (*cusF*, *cusB*, *cusC*, *cusA*, *cusS*, *cusR*, and *cusE*) in *A2/A1* and *A3/A1*, *B2/B1* and *B3/B1*, and *C2/C1* and *C3/C1* are shown in [Figure 3](#F3){ref-type="fig"}. CusS-CusR TCS showed the highest expression in group C.

![Relative expression of AcrAB-TolC in groups A, B, and C. Efflux pump AcrAB-TolC-associated genes: *soxS*, *acrB*, *rarA*, *ramA*, *ramR*, *marA*, *tolC*, and *acrA*. Group B showed higher expression than groups A and C.](fmicb-10-03159-g002){#F2}

![Relative expression of CusS-CusR TCS in groups A, B, and C. CusS-CusR TCS associated genes: *cusF*, *cusB*, *cusC*, *cusA*, *cusS*, *cusR*, and *cusE*. Group C showed higher expression than groups A and B.](fmicb-10-03159-g003){#F3}

Tigecycline Resistance-Associated Genes {#S3.SS4}
---------------------------------------

We detected the AcrEF-TolC efflux pump and OqxAB-TolC efflux pump in *A2*, *A3*, *B2*, *B3*, *C2*, and *C3*. In contrast, the *acrE*, *acrF*, *oqxA*, and *oqxB* genes did not show higher expression than *A1*, *B1*, and *C1*. The *ramR*, *tex (T)*, and *tet (A)* genes contained no mutations.

Effect of Deletion and Complementation {#S3.SS5}
--------------------------------------

Successfully built a non-trace cusS gene deletion strain *△C3* and the complemented strain *C-△C3*, and then verified by RT-PCR of the *cusR* gene in Δ*C3* showing no expression. The tigecycline MIC of *△C3* was decreased to 4 μg/mL and that of *C-△C3* was recovered to 32--4 μg/mL, and the expression of *cusFBCA* correspondingly decreased and increased significantly.

Discussion {#S4}
==========

In the present study, we successfully screened three groups of tigecycline-resistant strains by RNA-sequencing, followed by annotation with biological information. We found that the AcrAB-TolC efflux pump system was highly expressed in group B, indicating that this system plays an essential role in the development of CRKP resistance to tigecycline. The AcrAB-TolC efflux pump is involved in resistance-nodulation cell division and has been reported to be resistant to several types of antibiotics ([@B29]; [@B4]; [@B27]). However, [@B19] reported that the IS5 insertion element increased the MIC of tigecycline by four-fold and was not dependent on the functional AcrAB-TolC efflux pump, suggesting that the AcrAB-TolC efflux pump is not the only mechanism causing tigecycline resistance. [@B12] reported that RamR is a repressor that prevents the overexpression of *ramA*; when *ramR* is mutated, *ramA* is overexpressed, leading to tigecycline resistance; this mechanism was confirmed by [@B18]. However, in the current study, no mutation in *ramR* was detected.

[@B28] reported that impairment of AcrAB-TolC function upregulates *acrEF* quinolone resistance in *E. coli*. Thus, we also detected *acrE* and *acrF*, but no increase in expression was observed. [@B14] evaluated 43 strains each of tigecycline-non-susceptible *KP* and tigecycline-susceptible *KP*, and found that the overexpression of OqxAB efflux pumps was a major cause of tigecycline-non-susceptible *KP* resistance to tigecycline. However, the evolved strains in this study did not show an increase in their expression. Furthermore, the genes *tex(T)* and *tet(A)*, which are associated with tigecycline resistance, also did not contain mutations, indicating that these genes were not involved in tigecycline resistance in groups A, B, and C.

Andrade ([@B2]) showed that multidrug-resistant *CTX-M*-(15, 9, and 2) -- and *KPC-2*-producing *Enterobacter hormaechei* and *Enterobacter asburiae* isolates possessed a set of acquired heavy metal tolerance genes including a chromosomal sil operon (for acquired silver resistance). [@B26] also indicated that mercury/silver resistance genes were associated with antibiotic resistance. [@B9] reported that cryptic Ag + resistance pertaining to the sil operon is prevalent and readily activated in particular genera (*Enterobacter* and *Klebsiella*). [@B8] reported that CusCFBA had a narrow substrate spectrum transporting Cu (I) and Ag (I); in this research, the MIC of tigecycline and the expression of c*usCFBA* presented significant changes after deletion and complementation of *cusR*. The c*us* system was clearly elaborated by [@B20], however, further research is necessary to verify whether it is involved in cross-resistance or co-resistance to metal and resistance to antibiotics. In conclusion, we considered that in group C, the CusS-CusS TCS was activated and resistance was induced in *C2/C3* strains to tigecycline.

We recognize some limitations to our study. The strains in group A did not show any changes in AcrAB-TolC efflux pump-related and CusS-CusR TCS-related gene expression. Additionally, genes associated with tigecycline resistance such as *acrE*, *acrF*, *oqxA*, and *oqxB* did not show increased expression, and *tex (T)* and *tet (A)* did not contain any mutations. Thus, other mechanisms may have caused *A2* and *A3* resistance to tigecycline, which requires additional analysis.

Conclusion {#S5}
==========

Despite these limitations, we found that the increased expression of the CusS-CusR TCS, which is associated with Cu and Ag resistance, mediated CRKP resistance to tigecycline, which may become a novel target of antibiotics. Thus, in cases where the common mechanisms are not identified as mediators of tigecycline resistance, the presence of high CusS-CusR TCS expression may be considered.
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Transcriptome sequencing results of groups B and C.

###### 

Click here for additional data file.
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